Literature DB >> 11779579

Renal effects of glucagon-like peptide in rats.

Carol Moreno1, Mahesh Mistry, Richard J Roman.   

Abstract

The present study examined the effects of recombinant glucagon-like peptide-1-(7-36)amide (rGLP-1) on renal hemodynamics and excretory function in innervated and denervated kidneys of anesthetized rats. Intravenous infusion of rGLP-1 at a dose of 1 microg x kg(-1) x min(-1) increased urine flow and Na(+) excretion 13-fold in the innervated kidney. The natriuretic and diuretic response to rGLP-1 was attenuated in the denervated kidney in which urine flow and Na(+) excretion only increased 3-fold. Fractional excretion of Li(+), an index of proximal tubular reabsorption, increased 219% in the innervated kidney but only 54% in the denervated kidney during infusion of rGLP-1. The diuretic and natriuretic response to rGLP-1 was associated with an increase in glomerular filtration rate (39%) in the innervated kidney, but it had no effect on glomerular filtration rate in the denervated kidney. These results indicate that the natriuretic and diuretic effects of rGLP-1 are due to inhibition of Na(+) reabsorption in the proximal tubule. It also increases glomerular filtration rate in kidneys with an intact renal innervation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11779579     DOI: 10.1016/s0014-2999(01)01542-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  33 in total

Review 1.  GLP-1 Agonists and Blood Pressure: A Review of the Evidence.

Authors:  Aditya Goud; Jixin Zhong; Matthew Peters; Robert D Brook; Sanjay Rajagopalan
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

3.  Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats.

Authors:  Abu Sufiun; Kazi Rafiq; Yoshihide Fujisawa; Asadur Rahman; Hirohito Mori; Daisuke Nakano; Hiroyuki Kobori; Koji Ohmori; Tsutomu Masaki; Masakazu Kohno; Akira Nishiyama
Journal:  Hypertens Res       Date:  2015-01-15       Impact factor: 3.872

Review 4.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 5.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

6.  Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.

Authors:  Ming Zhang; Mélanie Robitaille; Aaron D Showalter; Xinyi Huang; Ying Liu; Alpana Bhattacharjee; Francis S Willard; Junfeng Han; Sean Froese; Li Wei; Herbert Y Gaisano; Stéphane Angers; Kyle W Sloop; Feihan F Dai; Michael B Wheeler
Journal:  Mol Cell Proteomics       Date:  2014-07-20       Impact factor: 5.911

Review 7.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

8.  Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin.

Authors:  Scott C Thomson; Ali Kashkouli; Zhi Zhao Liu; Prabhleen Singh
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

Review 9.  Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.

Authors:  Volker Vallon; Neil G Docherty
Journal:  Exp Physiol       Date:  2014-08-01       Impact factor: 2.969

Review 10.  Incretin-based therapies: viewpoints on the way to consensus.

Authors:  Michael A Nauck; Tina Vilsbøll; Baptist Gallwitz; Alan Garber; Sten Madsbad
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.